In compliance with current regulations, let us know which audience you belong to:
Espansione Group, the leading medical device company offering screening and treatment solutions for ocular conditions, and Reykjavik University (Iceland) are thrilled to announce the signing of a partnership between the univeristy’s Heilbrigdistaeknisetur (Institute of Biomedical and Neural Engineering) from Reykjavik University, Iceland.
We take the chance of this announcement to thank the Head of the Institute, Professor Paolo Gargiulo, for participating in this scientific cooperation. We also thank Dr. Sònia Travé Huarte, optometrist and researcher specializing in dry eye diagnostic and treatments, anterior ocular surface disease management, specialty contact lenses, and Meibomian gland dysfunction (MGD), to be part of the project as specialist in the field.
The main objectives of the collaboration are the following:
The institute will recruit 100 individuals and will assess the status of the Meibomian glands on the lower lid, and will monitor the subject for four weeks of treatment.
As far as both parties are aware at the time of publishing, the study will evaluate for the first time in scientific literature the immediate effect of a Light Modulation™ Low-level Light Therapy (LM™ LLLT) treatment.
On Reykjavick University
The role of Reykjavik University (RU) is to create and dissemi- nate knowledge in order to enhance the competitiveness and quality of life for individuals and society, guided by good ethics, sustainability, and responsibility.
The Institute of Biomedical and Neural Engineering (Heilbrigdistaeknisetur) is an internationally recognized research center established by the University Hospital Landspitali and Reykjavik University with the aim to improve healthcare processes and translational research in biomedicine.
Visit the university's website at en.ru.is
About Espansione Group
Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.
The company’s certified medical solutions leverage proprietary technologies such as Light Modulation™ Low-level Light Therapy (LM™ LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.
Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.
For more information, visit www.espansionegroup.it
Espansione Group Press Office
press@espansione.it
© 2022 Espansione Group, All Rights Reserved
Posted on November 30th, 2022 in Newsroom